711 related articles for article (PubMed ID: 23836234)
1. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.
Scheel TK; Rice CM
Nat Med; 2013 Jul; 19(7):837-49. PubMed ID: 23836234
[TBL] [Abstract][Full Text] [Related]
2. A Hepatitis C virus-host interaction involved in viral replication: toward the identification of antiviral targets.
Suzuki T
Jpn J Infect Dis; 2010 Sep; 63(5):307-11. PubMed ID: 20858994
[TBL] [Abstract][Full Text] [Related]
3. Profile of alisporivir and its potential in the treatment of hepatitis C.
Gallay PA; Lin K
Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
[TBL] [Abstract][Full Text] [Related]
4. HCV direct-acting antiviral agents: the best interferon-free combinations.
Schinazi R; Halfon P; Marcellin P; Asselah T
Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of hepatitis C virus infection by hydroxyzine and benztropine.
Mingorance L; Friesland M; Coto-Llerena M; Pérez-del-Pulgar S; Boix L; López-Oliva JM; Bruix J; Forns X; Gastaminza P
Antimicrob Agents Chemother; 2014 Jun; 58(6):3451-60. PubMed ID: 24709263
[TBL] [Abstract][Full Text] [Related]
6. Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects.
Lawitz EJ; Membreno FE
J Gastroenterol Hepatol; 2014 Aug; 29(8):1574-81. PubMed ID: 24852401
[TBL] [Abstract][Full Text] [Related]
7. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy.
Lee C
Arch Pharm Res; 2011 Sep; 34(9):1403-7. PubMed ID: 21975800
[TBL] [Abstract][Full Text] [Related]
8. [Hepatitis C virus: 25 years-old, the end?].
Pol S
Med Sci (Paris); 2013 Nov; 29(11):998-1003. PubMed ID: 24280503
[TBL] [Abstract][Full Text] [Related]
9. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
Tornai I
Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
[TBL] [Abstract][Full Text] [Related]
10. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
Ben Yakov G; Montano D; Abu Freha N; Etzion O; Dizingof V; Mushkalo A; Shwarts D; Monitin S; Takchick A; Zilberman D; Sikuler E; Fich A
Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
[TBL] [Abstract][Full Text] [Related]
11. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
[TBL] [Abstract][Full Text] [Related]
12. Mixing the right hepatitis C inhibitor cocktail.
Gelman MA; Glenn JS
Trends Mol Med; 2011 Jan; 17(1):34-46. PubMed ID: 21106440
[TBL] [Abstract][Full Text] [Related]
13. New Therapies for Hepatitis C Virus.
Polenakovik H
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
[TBL] [Abstract][Full Text] [Related]
14. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
15. New HCV therapies on the horizon.
Vermehren J; Sarrazin C
Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
[TBL] [Abstract][Full Text] [Related]
16. Modulation of host metabolism as a target of new antivirals.
Ikeda M; Kato N
Adv Drug Deliv Rev; 2007 Oct; 59(12):1277-89. PubMed ID: 17897752
[TBL] [Abstract][Full Text] [Related]
17. Impact of host and virus genome variability on HCV replication and response to interferon.
Schweitzer CJ; Liang TJ
Curr Opin Virol; 2013 Oct; 3(5):501-7. PubMed ID: 23835049
[TBL] [Abstract][Full Text] [Related]
18. Understanding the molecular mechanism(s) of hepatitis C virus (HCV) induced interferon resistance.
Qashqari H; Al-Mars A; Chaudhary A; Abuzenadah A; Damanhouri G; Alqahtani M; Mahmoud M; El Sayed Zaki M; Fatima K; Qadri I
Infect Genet Evol; 2013 Oct; 19():113-9. PubMed ID: 23831932
[TBL] [Abstract][Full Text] [Related]
19. The hepatitis C virus life cycle as a target for new antiviral therapies.
Pawlotsky JM; Chevaliez S; McHutchison JG
Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890
[TBL] [Abstract][Full Text] [Related]
20. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
